Kangas ST, Salpéteur C, Nikièma V, et al. - Via a randomized controlled trial (the MANGO trial), experts examined the non-inferiority of a decreased ready-to-use therapeutic food (RUTF) dose in the management of uncomplicated severe acute malnutrition (SAM) compared with the standard dose. A total of 801 children 6–59 months of age were recruited and randomized individually into receiving a standard dose of RUTF throughout the treatment and a standard dose during the first two weeks, followed by a decreased dose from third treatment week onwards. Non-inferior weight gain velocity from admission to discharge and comparable recovery and length of stay in treatment were exhibited. Nonetheless, the decreased dose also led to a significantly slower height gain velocity in comparison with the standard dose. In conclusion, decreasing the RUTF dose given to children with SAM following two weeks of treatment did not diminish overall weight or mid-upper arm circumference gain velocity nor influence recovery or prolong treatment time. Nevertheless, it resulted in a small but important negative impact on linear growth, particularly among the youngest. Moreover, the potential impact of decreasing the RUTF dose in a routine program on treatment outcomes should be assessed prior to the scaling up.